Production (Stage)
MEI Pharma, Inc.
MEIP
$2.18
$0.03081.43%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -100.00% | -100.00% | 33.76% | 13.58% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -100.00% | -100.00% | 33.76% | 13.58% |
| Cost of Revenue | -59.33% | -52.40% | -56.68% | -67.02% | -69.20% |
| Gross Profit | -111.22% | -121.97% | -120.25% | 44,791.82% | 339.07% |
| SG&A Expenses | -60.91% | -54.23% | -36.87% | -29.02% | 1.38% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -59.94% | -53.38% | -46.83% | -52.05% | -56.46% |
| Operating Income | -171.50% | -235.39% | -185.65% | 178.36% | 160.71% |
| Income Before Tax | -221.06% | -292.59% | -213.22% | 155.84% | 169.06% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -221.06% | -292.59% | -213.22% | 155.84% | 169.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -221.06% | -292.59% | -213.22% | 155.84% | 169.06% |
| EBIT | -171.50% | -235.39% | -185.65% | 178.36% | 160.71% |
| EBITDA | -168.43% | -229.72% | -183.24% | 180.45% | 162.20% |
| EPS Basic | -221.06% | -292.59% | -213.22% | 155.84% | 169.03% |
| Normalized Basic EPS | -155.07% | -201.00% | -171.64% | 203.49% | 178.00% |
| EPS Diluted | -221.06% | -292.59% | -213.22% | 155.84% | 169.03% |
| Normalized Diluted EPS | -155.07% | -201.00% | -171.64% | 203.49% | 178.00% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.03% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |